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Erythema nodosum leprosum (ENL) is a systemic inflammatory complication occurring mainly 
in patients with lepromatous leprosy (LL) and borderline lepromatous leprosy. Prednisolone 
is widely used for treatment of ENL reactions but clinical improvement varies. However, 
there is little good in  vivo data as to the effect of prednisolone treatment on the pro- 
inflammatory cytokines in patients with ENL reactions. As a result, treatment and manage-
ment of reactional and post-reactional episodes of ENL often pose a therapeutic challenge. 
We investigated the effect of prednisolone treatment on the inflammatory cytokines TNF, 
IFN-γ, IL-1β, IL-6, and IL-17 and the regulatory cytokines IL-10 and TGF-β in the skin lesion 
and blood of patients with ENL and compared with non-reactional LL patient controls. 
A case–control study was employed to recruit 30 patients with ENL and 30 non-reactional LL 
patient controls at ALERT Hospital, Ethiopia. Blood and skin biopsy samples were obtained 
from each patient before and after prednisolone treatment. Peripheral blood mononuclear 
cells from patients with ENL cases and LL controls were cultured with M. leprae whole-cell 
sonicates (MLWCS), phytohemagglutinin or no stimulation for 6 days. The supernatants were 
assessed with the enzyme-linked immunosorbent assay for inflammatory and regulatory 
cytokines. For cytokine gene expression, mRNA was isolated from whole blood and skin 
lesions and then reverse transcribed into cDNA. The mRNA gene expression was quantified 
on a Light Cycler using real-time PCR assays specific to TNF, IFN-γ, IL-β, TGF-β, IL-17A, 
IL-6, IL-8, and IL-10. The ex vivo production of the cytokines: TNF, IFN-γ, IL-1β, and IL-17A 
was significantly increased in untreated patients with ENL. However, IL-10 production was 
significantly lower in untreated patients with ENL and significantly increased after treatment. 
The ex vivo production of IL-6 and IL-8 in patients with ENL did not show statistically 
significant differences before and after prednisolone treatment. The mRNA expression in 
blood and skin lesion for TNF, IFN-γ, IL-1β, IL-6, and IL-17A significantly reduced in patients 
with ENL after treatment, while mRNA expression for IL-10 and TGF-β was significantly 
increased both in blood and skin lesion after treatment. This is the first study examining the 
effect of prednisolone on the kinetics of inflammatory and regulatory cytokines in patients 
with ENL reactions before and after prednisolone treatment. Our findings suggest that pred-
nisolone modulates the pro-inflammatory cytokines studied here either directly or through 
suppression of the immune cells producing these inflammatory cytokines.
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inTrODUcTiOn
Leprosy is a chronic disease caused by Mycobacterium leprae, 
an acid-fast bacillus whose clinical spectrum correlates with the 
host immune response. It mainly infects the skin and peripheral 
nerves. There are five-clinical forms of leprosy called spectrum 
with the localized tuberculoid leprosy (TT) and the generalized 
lepromatous leprosy (LL) forming the two poles of the spectrum 
(1). Erythema nodosum leprosum (ENL) is an immune-mediated 
inflammatory complication causing high morbidity in affected 
leprosy patients (2). The clinical manifestation of ENL includes 
tender erythematous crops of skin lesions and systemic features 
of disease including fever, neuritis and bone pain (3). ENL occurs 
mainly in patients with LL and borderline lepromatous (BL) lep-
rosy before, during, or after successful completion of multidrug 
treatment (MDT) (4).
Erythema nodosum leprosum reaction is associated report-
edly with changes in cytokine profiles (5, 6). Cytokines are low 
molecular weight soluble proteins which mediate the cross-talk 
between the different cells of the immune system. They play a 
central role in the recruitment of the immune cells, the clonal 
development of the lymphocytes, the innate immune response 
and the effector response of most immune cells. These complex 
regulatory networks of cytokines often determine the clinical 
course of infections and the outcome (7).
In leprosy, cytokine research focused mainly on the associa-
tion of different cytokine profile with the spectrum of the disease 
specifically with the Th1–Th2 cytokine profiles (5, 8, 9). The 
immune response to M. leprae in tuberculoid (TT) patients is 
associated with Th1 cytokines (IFN-γ and TNF) whereas LL 
patients are characterized by Th2 (IL-4, IL-5) cytokines pro-
duction (6, 10–15). However, recent studies have shown that a 
distinct cytokine profile associated with a specific clinical form 
and reactions has not been attained (16–18).
The immune response to M. leprae is cytokine mediated, 
whereas the involvement of cytokines in ENL reaction is less 
understood. Literature reveals controversial results on the 
cytokines profile which are involved in ENL reaction. The pres-
ence of both Th1- and Th2-type cytokines in ENL lesions as well 
as in the sera of ENL patients has been reported by some authors 
(19–21). However, others reported that only Th1 cytokines are 
involved in the pathogenesis of ENL (6, 19, 22, 23). Yet other 
authors suggested that there is no clear association of either Th1 
or Th2 cytokine secretion profile in leprosy patients with ENL 
reactions compared to non-reactional LL patients (8). In addition 
to the Th1- and Th2-driven cytokines, IL-17 has been identified 
as a new subset of cytokine recently reported associated with ENL 
reactions (24–26).
Erythema nodosum leprosum reaction is treated with pred-
nisolone or with thalidomide. Thalidomide is not available in 
most leprosy endemic countries such as Ethiopia due to its 
severe side effects. Prednisolone is an immunosuppressor drug 
used for the treatment of chronic inflammatory diseases. The 
anti-inflammatory role of prednisolone is mainly due to its abil-
ity to suppress or inhibit the activation of transcription factors 
NF-kβ (27). NF-kβ regulates genes encoding for IL-1β, TNF, 
IL-2, and inducible nitric oxide synthase (28, 29). In leprosy 
reactions, although the results are conflicting, treatment of ENL 
with prednisolone has been correlated with downregulation of 
inflammatory cytokines, such as IL-1β, TNF, IFN-γ, and IL-17 
(20, 22, 30). On the other hand, other studies reported the selec-
tive downregulation of regulatory cytokines after prednisolone 
treatment (6, 31).
Although oral prednisolone is widely used for treatment of 
ENL, clinical improvement varies in which more than 40% of 
cases do not show clinical improvement (32). High recurrent 
episodes and flare-ups are common in these patients. However, 
there is little good in vivo data as to the effect of prednisolone 
treatment on the pro-inflammatory cytokines. As a result, treat-
ment and management of reactional and post-reactional episodes 
of ENL often pose a therapeutic challenge to leprologists.
We investigated the effect of prednisolone treatment on the 
inflammatory cytokines TNF, IFN-γ, IL-1β, IL-6, and IL-17 and 
the regulatory cytokines IL-10 and TGF-β in the skin lesion and 
blood of patients with ENL and compared with non-reactional 
LL patient controls. Our aim was to compare events at the local 
site of infection (i.e., the skin lesion) and the systemic effects 
of the prednisolone on the cytokine production and their gene 
expression before, during, and after treatment. LL patients with-
out reactions were included as controls. We hypothesized that 
prednisolone treatment would downregulate the inflammatory 
cytokines and upregulate regulatory cytokines both locally in the 
skin and systemically in the blood and hence establish cytokine 
homeostasis.
MaTerials anD MeThODs
study Design
A case–control study with follow-up for 28 weeks after the ini-
tiation of prednisolone treatment was used to recruit 30 patients 
with ENL reaction and 30 non-reactional LL patient controls 
between December 2014 and January 2016 at ALERT hospital, 
Ethiopia.
ethical considerations
Informed written consent for blood and skin lesion biopsies were 
obtained from patients following approval of the study by the 
Institutional Ethical Committee of London School of Hygiene 
and Tropical Medicine, UK (#6391), AHRI/ALERT Ethics Review 
Committee, Ethiopia (P032/12) and the National Research Ethics 
Review Committee, Ethiopia (#310/450/06). All patient data were 
analyzed and reported anonymously.
Patient recruitment
Leprosy patients were recruited at ALERT Hospital, Addis Ababa, 
Ethiopia. The patients were classified clinically and histologi-
cally on the leprosy spectrum based on the Ridley–Jopling (RJ) 
classification schemes (1). ENL was clinically diagnosed when a 
patient with BL or LL leprosy had painful crops of tender cutane-
ous erythematous skin lesions (3). New ENL was defined as the 
occurrence of ENL for the first time in a patient with LL or BL. LL 
was clinically diagnosed when a patient had widely disseminated 
nodular lesions with ill-defined borders and BI above 2 (2). 
3Negera et al. Cytokines in ENL
Frontiers in Immunology | www.frontiersin.org February 2018 | Volume 9 | Article 189
Patients with ENL were treated according to the World Health 
Organization (WHO) treatment guideline with steroids that 
initially consisted of 40 mg oral prednisolone daily and the dose 
was tapered by 5 mg every fortnight for 24 weeks. All patients 
were received WHO-recommended leprosy MDT.
Blood and skin lesion Biopsy samples
Twenty microliters of venous blood were collected into sterile 
BD Heparinized Vacutainer® tubes (BD, Franklin, Lakes, NJ, 
USA) before treatment, during treatment on week 12, and 
after treatment on week 24 from each patient and used for 
peripheral blood mononuclear cell (PBMC) isolation. In addi-
tion, 2 mL of blood was collected into PAXgene® Blood RNA 
Tubes (PreAnalytix, GmbH, Switzerland) before, during, and 
after prednisolone treatment for mRNA isolation and stored 
at −80°C. Six-millimeter punch biopsy was taken from each 
patient before and after prednisolone treatment into a Nunc® 
tube containing 1  mL RNAlater® solution (Thermo-Fisher 
Scientific) and was kept at −20°C for 48 h and then transferred 
to −80°C freezer. ENL and LL lesions for biopsy sample were 
identified and marked by a dermatologist and then biopsy 
samples were taken from the marked area by trained research 
nurses under supervision.
PBMc isolation, storage, and Thawing
Peripheral blood mononuclear cells were separated by density 
gradient centrifugation at 800 × g for 25 min on Ficoll–Hypaque 
(Histopaque, Sigma Aldrich, UK) as described earlier (33, 34). 
Cells were washed three times in sterile 1× phosphate-buffered 
saline (Sigma Aldrich®, UK) and re-suspended with 1  mL 
of Roswell Park Memorial Institute (RPMI medium 1640 
(1×) + GlutaMAX™ + Pen-Strip GBICO™, Life technologies™, 
UK). Cell viability was determined by 0.4% sterile Trypan Blue 
solution (Sigma Aldrich®, UK), the viability was between 94 and 
98%. PBMC freezing was performed using a cold freshly prepared 
freezing medium composed of 20% fetal bovine serum (FBS, heat 
inactivated, endotoxin tested ≤5 EU/ml, GIBCO® Life technolo-
gies, UK), 20% dimethyl sulfoxide in RPMI medium 1640 (1×). 
Cells were kept at −80°C for 2–3 days and transferred to liquid 
nitrogen until use. Cell thawing was done as described (35). The 
procedure is briefly described as follows: cells were incubated in a 
water bath (37°C) for 30 s until thawed half way and re-suspended 
in 10% FBS in RPMI medium 1640 (1×) (37°C) containing 
1/10,000 benzonase until completely thawed, washed two times 
(5 min each), and counted. The percentage viability obtained was 
above 90%.
PBMc stimulation with M. leprae  
Whole-cell sonicate (Wcs)
Total PBMCs (200,000 cells/well) were added in triplicate into 
96-well U-bottom tissue culture plates and cultured with 10 mg/mL 
irradiated armadillo-derived M. leprae WCS (kindly sup-
plied by Dr. J. S. Spencer through the NIH/NIAID “Leprosy 
Research Support” Contract N01 AI-25469 from Colorado State 
University), 1 mg/mL phytohemagglutinin or AIM-V medium at 
37°C with 5% CO2 and 70% humidity. After 6 days, supernatants 
were collected and kept frozen until used in enzyme-linked 
immunosorbent assay (ELISA).
cytokine Measurement by elisa
Supernatants were tested for cytokines using a Ready-Set-Go! ® 
Sandwich ELISA. Capture and biotinylated detection antibod-
ies directed against IFN-γ, TNF, IL-1β, IL-6, IL-10, IL-10, and 
IL-17A were purchased from eBioscience (Affymetrix, eBiosci-
ence, UK). A 96-well flat-bottom Nunc MaxiSorp® ELISA plates 
(Affymetrix, eBioscience, UK) were used. Standards for each 
cytokines were prepared by serial dilution as recommended 
by the supplier (Affymetrix, eBioscience, UK). Detection was 
performed with avidin-horseradish peroxidase (Avidin-HRP) 
conjugated with tetramethylbenzidine following the supplier’s 
procedure (Affymetrix, eBioscience, UK). For all plates, the 
optical density (OD) at 450 nm was measured using an ELISA 
plate reader (Microplate reader; Bio-Rad, Richmond, CA, USA). 
A curve fit was applied to each standard curve according to the 
manufacturer’s manual. Sample concentrations were interpolated 
from these standard curves. The assays were sensitive to over 
concentration ranges from 2 to 200 pg/mL for IL-6 and IL-17A, 
from 2 to 250 pg/mL for IL-8, from 2 to 300 pg/mL for IL-10, and 
from 4 to 500 pg/mL for TNF, IFN-γ, and IL-1β.
rna isolation and reverse Transcription
Isolation of RNA from whole blood and skin lesion biopsies 
stored in RNAlater™ (Ambion, Austin, TX, USA) was performed 
using PAXgene Blood RNA Kit and RNeasy Fibrous Tissue Kit 
(QIAGEN Crawley, West Sussex, United Kingdom), respectively, 
according to the manufacturer’s protocol. DNase I (QIAGEN) 
was included for all RNA preparations for DNA digestion. RNA 
yield was determined using a NanoDrop 2000, spectrophotom-
eter (Thermo Scientific, Epsom, UK) and integrity was checked 
by agarose gel electrophoresis. For all samples, complementary 
DNA (cDNA was synthesized on the same day to avoid the risk of 
RNA degrades during storage). cDNA was synthesized from RNA 
(200  ng/reaction mixture) using High Capacity cDNA Reverse 
Transcriptase Kit (AB Applied Biosystems, UK). Reactions were 
incubated in an ABI9700 Programmable Thermal Cycler (Applied 
Biosystems, Foster City, CA, USA) for 10 min at 25°C followed 
by 120 min at 37°C and 5 min at 85°C and then cooling to 4°C.
Primers and Quantitative Polymerase 
chain reaction
Primers between 20 and 24  nt in length were designed across 
intron/exon boundaries on mRNA sequence obtained from the 
Nation Centre for Biotechnology Information database (NCBI) 
to give a product between 100–500 bp. All primer sequences were 
blasted on the NCBI data bank to confirm their specificity. Custom 
synthesis of oligonucleotide primers was performed by Sigma-life 
science and provided in desalted form. The nucleotide sequences 
of the forward and reverse primers, respectively, used in this study 
were as follows: for IL-10, 5′-TGAGAACCAAGACCCAGACA-3′ 
and 5′-TCATGGCTTTGTAGATGCCT-3′; for TNF, 5′-AGCC 
CATGTTGTAGCAAACC-3′ and 5′-GCTGGTTATCTCTCAG 
CTCCA-3′; for IL-17A, 5′-AGACCTCATTGGTGTCACTGC-3′ 
and 5′-CTCTCAGGGTCCTCATTG CG-3′; for Il-6, 5′-TTCGGT 
FigUre 1 | PCR optimization: (a) the optimization threshold of housekeeping gene (HuPO) and TNF-α; (B) the optimization cycle threshold for IL-1β, IL-10, and 
IL-17A; (c) the cycle threshold of housekeeping gene for multiple samples; and (D) the melt curve analysis. The peak curve indicates the primer amplified the same 
region of all samples and primer-dimer is not detected as there is only one such peak.
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CCAGTTGCCTTCTC-3′ and 5′-TACATGTCTCCTTTCTCA 
GGGC-3′; or IL-1β, 5′-AGCCCCAGCCAACTCAATTC-3′ and 
5′-CATGGAGAACAC CACTTGTTGC-3′; for IFN-γ: 5′-GGC 
TTTTCAGCTCTGCATCG-3′ and 5′-TCTGTCAC TCTCCTC 
TTTCCA-3′; for IL-8: 5′-ACCGGAAGGAACCATCTCAC-3′ and 
5′- AAAC TGCACCTTCACACAGAG-3′; for TGF-β: 5′-ACAT 
CAACGCAGGGTTCACT-3′ and 5′- GAAGTTGGCATGGTAG 
CCC-3′; for human acidic ribosomal protein (HuPO) house-
keeping gene: 5′-GGACTCGTTTGTACCCGTTG-3′ and 5′-GG 
ACTCGTTTGTA CC CG TTG-3′.
Real-time quantitative PCR for all genes was performed on the 
Rotor-Gene™ 3000 programmable thermal cycler (Corbett Life 
Science, Qiagen, Crawley, UK) using Roter-gene® SYBR® Green 
PCR Kit (Qiagen, Crawley, UK). The Rotor-Gene conditions were 
set as follows: Initial activation step (polymerase activation) was 
achieved by incubating at 95°C for 15 min, 40 cycles of denatura-
tion at 95°C for 5 s, annealing at 60°C for 10 s, extension at 72°C 
for 20 s, and fluorescence acquisition for 5 s at 72°C. The primer-
dimer formation was checked by melting curve analysis. Melting 
point data were obtained by increasing the temperature from 50°C 
to 99°C by 1°C on each step. The interval between increases in 
temperature was 30 s for the first step and then 5 s for subsequent 
steps. An assay control was included from mRNA extraction to 
the amplification steps. For mRNA extraction, one assay control 
per batch was used. The assay control included all buffers except 
the sample and was processed under identical conditions with the 
samples. The same assay control was used during cDNA synthesis 
and real-time quantitative PCR (Figure 1).
statistical Methods
ELISA Data
The OD of each sample for each cytokine was obtained by the 
ELISA reader. The OD was converted to concentration (pg/mL) 
by microplate manager 6. Unpaired t-test was used to compare 
the relative concentration of the cytokines production in patients 
with ENL and LL controls. For comparing the cytokine concentra-
tion in patients with ENL before and after treatment, paired t-test 
was used. Results are presented as mean ±  SEM with P-values 
with a cut–off 0.05. SE was chosen since the primary objective of 
the study was to measure how the mean of the sample is related to 
the mean of the underlying population. SE takes SD and sample 
size into account.
Real-time Quantitative PCR
Real-time quantitative PCR for the mRNA gene expression of 
target genes, the relative threshold cycle value (CT) comparison 
method was used. The relative gene expression was analyzed by 
using the 2−ΔΔ CT method (36). The CT value is the threshold num-
ber for the amplification of the target gene. Cikos et al. compared 
the six different methods currently used for real-time PCR data 
analysis and has shown that the best results were obtained with 
the relative standard curve (ΔCT) method and the least coefficient 
5Negera et al. Cytokines in ENL
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of variation (ΔCV). The CT values were obtained for the target 
gene and control gene (HuPO) for each patient sample at each 
time point. Then, the difference in CT value was obtained by sub-
tracting the CT of the target gene from the CT of the control gene 
and designated as ΔCT. To compare the target gene expression 
in patients with ENL and LL controls, ΔΔCT was obtained by 
subtracting the ΔCT of LL patient control from the ΔCT of the 
patient with ENL. Then, the fold change was obtained by using 
the formula 2−ΔΔ CT. similarly, for the comparison of the relative 
target gene expression in patients with ENL before and after treat-
ment, ΔΔCT was obtained by ΔCT (after) minus ΔCT (before). 
Then the fold change for target gene expression from the baseline 
(before treatment) was given by 2−ΔΔ CT. Unpaired t-test was used 
to compare the fold change of each target gene for patients with 
ENL compared to LL patient controls. To compare the expression 
level of the desired gene in patients with ENL before and after 
treatment, paired t-test was used.
resUlTs
Results are presented in two sections. First, we presented the 
results of cytokine production and then followed by the gene 
expressions. Within each section, we presented first the com-
parisons made between ENL and LL controls and then followed 
by the comparisons made within ENL patients at different time 
points.
Patient clinical Background
Thirty LL patients with ENL reaction and 30 LL patient controls 
without ENL reaction were recruited between December 2014 
and January 2016. The male to female ratio was 2:1 with a median 
age of 27.5 (range: 18–56) years in patients with ENL and 3:1 
with a median age of 25.0 (range: 18–60) years in patients with 
non-reactional LL controls. All ENL patients were untreated 
with corticosteroid before recruitment. At time of recruitment, 
10 ENL patients were previously untreated with MDT, 15 are on 
MDT and 5 were completed MDT treatment. Twenty-one LL 
patients were about to start MDT, 9 were on MDT at recruitment.
increased In Vitro inflammatory cytokine 
Production in Untreated enl Patients 
compared to ll controls
The mean production of TNF in response to M. leprae WCS 
stimulation was significantly higher (83.6.4 ±  18.82  pg/mL) in 
the culture supernatants of PBMCs from untreated ENL patients 
than from LL patient controls (19.4 pg/mL ± 10.44) (P ≤ 0.05). 
During treatment, the level of TNF production decreased to 
10.7 pg/mL in patients with ENL while it was increased to 36. 
9 pg/mL in LL patient controls. After treatment, TNF production 
was not significantly different between the two groups (Figure 2).
Patients with ENL reactions had a significantly higher (1361 pg/mL  
±  309.6) IFN-γ production than the LL patient controls 
(280.1 pg/mL ± 269.80) before treatment (P ≤ 0.05). However, 
during treatment, the level of IFN-γ production was significantly 
decreased in patients with ENL to 304.4  pg/mL ±  119.6 while 
it was increased in LL patient controls to 1158.0 pg/mL ± 549.2 
(P ≤ 0.05). The level of IFN-γ production was not significantly 
different in both groups after treatment (Figure 2).
Although the amount of IL-1β production was similar in 
patients with ENL and LL controls before and during treatment, 
patients with ENL had much lower production of IL-1β than LL 
patient controls after treatment (P ≤  0.05). Higher production 
of IL-17A was obtained in patients with ENL cases compared to 
LL patient controls before treatment (P ≤ 0.005). Although the 
in vitro production of IL-17A was considerably decreased after 
treatment in patients with ENL, it still remained higher than in 
LL patient controls (P ≤ 0.05) (Figure 2).
The in vitro response of IL-6 production was higher in patients 
with ENL than in LL controls before treatment (P  ≤  0.005). 
However, during and after treatment, the in vitro IL-6 production 
was not significantly different in both groups. On the other hand, 
the level of IL-8 production was found to be higher in patients 
with ENL than in LL controls throughout the study period 
(P ≤ 0.05) (Figure 2).
The IL-10 production was considerably lower in patients with 
ENL (18.59 pg/mL ± 4.05) than in LL patient controls (122.6 pg/mL  
±  23.18) before treatment (P  <  0.0001). Interestingly, after 
treatment, the level of IL-10 production was significantly 
increased to 87.78 pg/mL ± 22.49 in patients with ENL while 
it was substantially decreased to 4.91  pg/mL ±  2.160 in LL 
patient controls and the difference was statistically significant 
(P ≤ 0.001) (Figure 2).
In conclusion, the in vitro production of the cytokines TNF, 
IFN-γ, IL-17A, IL-6, and IL-8 were higher in patients with ENL 
than in LL patient controls before treatment while IL-10 was sig-
nificantly lower in patients with ENL than in LL patient controls 
at recruitment.
A receiver operator characteristic (ROC) curve plot for the 
accuracy of a single cytokine to discriminate between patients 
with ENL and LL controls was produced. The most accurate 
cytokines that differentiate between patients with ENL and LL 
controls were as follows: TNF, IL-6, IL-17A, IL-1β, IL-8, IFN-γ, 
and IL-10 with the corresponding of area under the curves 
(AUCs) of 0.779, 0.763, 0.745, 0.695, 0.667, 0.557, and 0.710, 
respectively (Figure 3).
Principal Component Analysis
Principal component analysis with varimax rotation was con-
ducted to assess the cytokine variables in order to summarize 
them by reducing the dimension of the dataset into principal 
components (Figure 4A). A loading score statistic was used to 
select the principal components most associated with the out-
come variable (ENL). The assumption of independent sampling 
was met. The assumptions of normality, linear relationships 
between pairs of variables, and the variables being correlated at a 
moderate level were checked.
The component plot in rotated space (Figure 4B) shows how 
closely related the cytokines are to each other and to the two 
components. This plot of the component loadings shows that 
IL-6, IL-1β, and IL-8 all load highly and positively on the first 
component. IL-10 and TNF had near zero on the first compo-
nent, but load highly on the second component. IL-17A loads 
moderately on the first component while IFN-γ loads moderately 
FigUre 2 | Comparison of the levels of in vitro production of TNF, IFN-γ, IL-β and IL-17A, IL-6, IL-8, and Ll-10 in culture supernatants of peripheral blood 
mononuclear cells from patients with erythema nodosum leprosum (ENL) and lepromatous leprosy (LL) controls before and after treatment. Statistical test: unpaired 
t-test, α = 0.05. *P ≤ 0.05; ** P ≤ 0.005. Bar graphs show mean ± SEM.
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FigUre 3 | Receiver operator characteristic (ROC) curves showing the accuracies of individual cytokines in discriminating between patients with ENL and LL 
controls before treatment. AUC = area under the curve.
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on component 2. The cytokine levels of IL-6, IL-1β, IL-8, and 
IL-17 loaded together on the first component with loading coef-
ficient of 0.860, 0.776, 0.704, and 0.472, respectively, explaining 
42.274% of the total variation in the cytokine study. Component 
2 is determined by three cytokines: IL-10, TNF, and IFN-γ with 
component loading coefficient of 0.899, 0.906, 0.120, respectively, 
and explaining 20.714% of the variation.
Decreased In Vitro inflammatory cytokine 
Production in enl Patients after 
Prednisolone Treatment
The levels of IFN-γ, IL-17A, TNF, IL-6, IL-8, Il-1β, and IL-10 
production in response to M. leprae WCS before, during, and 
after treatment were compared within ENL. The in vitro TNF 
production in response to M. leprae WCS stimulation was 
considerably higher (83.6  pg/mL ±  18.82) before treatment 
than during treatment (10.7 pg/mL ± 2.79) (P ≤ 0.001). After 
treatment, it was slightly increased to 25.4 pg/mL ± 8.88 than 
during treatment but was still lower than the amount obtained 
before treatment (P ≤  0.005). Likewise, the in  vitro produc-
tion of IFN-γ in response to M. leprae WCS was considerably 
higher before treatment (1361.0 pg/mL ± 309.6) than during 
treatment (304.4 pg/mL ± 119.6) (P ≤ 0.05) and after treatment 
(328.2 pg/mL ± 190.3) (P ≤ 0.05) (Figure 5).
The level of IL-1β and IL-17A production were also found to 
be higher before treatment than during and after prednisolone 
treatment of patients with ENL. Although IL-6 production was 
appreciably decreased during treatment, it was increased after 
treatment and statistically a significant difference was not revealed 
before or after treatment. Unlike IL-6, IL-8 production did not 
show any significant change before, during and after treatment 
(Figure 5). On the other hand, the level of IL-10 production was 
very low before and during treatment but substantially increased 
after treatment (Figure 5).
In summary, the in vitro production of IFN-γ, IL-17A, TNF, 
and IL-1β to M. leprae WCS stimulation were higher before 
prednisolone treatment and have shown a significant reduction 
after treatment indicating the possible association of these pro-
inflammatory cytokines and ENL reaction. On the other hand, the 
in vitro production of IL-10 was noticeably low before treatment 
and significantly increased after treatment showing its possible 
regulatory activity. IL-6 and IL-8 did not show significant change 
before and after treatment of patients with ENL.
inflammatory cytokines gene expression 
Upregulated in the Peripheral Blood  
of Untreated enl Patients compared  
to ll controls
To investigate the cytokine gene expression in blood and skin 
biopsies, a fold change (FC) was used to compare the levels of 
these gene expressions in patients with ENL and LL controls as 
well as among patients with ENL before and after treatment.
FigUre 4 | (a) Scree plot showing the in vitro cytokine production in culture supernatants of peripheral blood mononuclear cells (PBMCs) from patients with 
erythema nodosum leprosum (ENL). The PCs have eigen values >1 are taken as the most significant components explaining variability in the data; (B) the 
component plot in rotated space showing visual representation of the loadings plotted in a 2-dimensional space.
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FigUre 5 | Comparison of the levels of in vitro cytokine production in culture supernatants of peripheral blood mononuclear cells (PBMCs) from patients with 
erythema nodosum leprosum (ENL) before and after treatment. Statistical test: paired t-test, α = 0.05. *P ≤ 0.05; **P ≤ 0.005; ***P < 0.001; ****P < 0.0001.  
Error bars show mean ± SEM.
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TaBle 3 | Cytokine mRNA expression in the blood samples from erythema 
nodosum leprosum before and after treatment.
cytokine ΔΔcT Fc P-value gene expression 
after treatment
TNF 1.19 0.44 0.0497* Decreased
IFN-γ 1.61 0.33 <0.0001* Decreased
IL-1β 1.56 0.34 0.0043* Decreased
IL-6 1.60 0.33 <0.0001* Decreased
IL-8 0.48 0.72 0.0790 No change
IL-10 −1.32 2.50 <0.0001* Increased
IL-17A 2.34 0.20 <0.0001* Decreased
TGF-β 0.24 0.85 0.7160 No change
Statistical test: paired t-test, α = 0.05. ΔΔCT = delta delta CT; FC = fold change; 
* = significant at α = 0.05.
TaBle 1 | Cytokine mRNA expression in the blood samples from patients with 
erythema nodosum leprosum and lepromatous leprosy controls before and after 
treatment.
gene of interest Before treatment after treatment
ΔΔcT Fc P-value ΔΔcT Fc P-value
TNF −1.73 3.31 0.0047* 0.00 1.00 0.9989
IFN-γ −1.27 2.42 0.0044* 0.08 0.95 0.8804
IL-1β −1.23 2.34 0.1085 −0.24 1.18 0.7333
IL-6 −2.59 6.01 0.0003* −0.99 1.99 0.1167
IL-8 −1.68 3.19 <0.0001* −0.81 1.75 0.243
IL-10 0.83 0.56 0.1552 0.28 0.82 0.5882
IL-17A −1.84 3.58 0.0002* 1.12 0.46 0.0502
TGF-β −0.07 1.05 0.8724 −2.27 4.82 0.0119*
Statistical test: unpaired t-test, α = 0.05, ΔΔCT = delta delta CT, FC = fold change, 
* = significant at α = 0.05.
TaBle 2 | Cytokine mRNA expression in the skin biopsy samples from patients 
with erythema nodosum leprosum and lepromatous leprosy controls before and 
after treatment.
gene of interest Before treatment after treatment
ΔΔcT Fc P-value ΔΔcT Fc P-value
TNF −1.03 2.04 0.0033* −0.09 1.07 0.89
IFN-γ −2.01 4.01 0.0058* −0.32 1.25 0.5224
IL-1β −2.67 6.35 0.0006* −0.24 1.18 0.7333
IL-6 −2.41 5.30 0.0015* −1.05 2.07 0.0438*
IL-8 −0.12 1.09 0.8465 −0.71 1.64 0.2333
IL-10 1.41 0.38  < 0.0001* −1.81 3.50 <0.0001*
IL-17A −1.58 2.99 0.0035* −0.13 1.10 0.281
TGF-β 0.31 0.8 0.4876 −0.63 1.55 0.3598
Statistical test: unpaired t-test, α = 0.05. ΔΔCT = delta delta CT, FC = fold change, 
* = significant at α = 0.05.
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The gene expression levels of TNF (FC  =  3.31), IFN-γ 
(FC =  2.42), IL-6 (FC =  6.01), IL-8 (FC =  3.19), and IL-17A 
(FC = 3.58) were significantly increased in the blood samples 
from patients with ENL compared to LL patient controls 
before treatment (P ≤ 0.05). However, after treatment, the gene 
expression levels of these cytokines did not reveal statistically 
a significant difference between ENL patients and LL controls 
(Table 1).
Although, the fold changes (FC) of mRNA gene expression for 
IL-1β and TGF-β were slightly increased before treatment in the 
blood samples from patients with ENL compared to LL patient 
controls, statistically a significant difference was not revealed. 
On the other hand, the mRNA gene expression for TGF-β was 
increased (FC =  4.82) in patients with ENL compared to LL 
patient controls after treatment (P ≤ 0.05). The level of IL-10 gene 
expression was not significantly different in the two groups before 
and after treatment (Table 1).
Except IL-10, the result of mRNA gene expression of the other 
cytokines (TNF, IFN-γ, IL-β, TGF-β, IL-17A, IL-6, and IL-8) 
was found to be consistent with the result of the corresponding 
in vitro cytokine production. Unlike the IL-10 cytokine produc-
tion in the culture supernatants in response to M. leprae WCS, its 
gene expression in patients with ENL did not reveal statistically 
significant difference compared to LL patient controls.
comparison of cytokine gene expression 
in skin Biopsy samples from Patients with 
enl and ll controls
The expression of mRNA in skin biopsies for TNF (FC = 2.04), 
IFN-γ (FC = 4.01), IL-1β (FC = 6.35), IL-6 (FC = 5.30), and 
IL-17A (FC =  2.99) were significantly higher (P ≤  0.005) in 
the biopsies from patients with ENL than in the biopsies from 
LL patient controls before treatment. However, except IL-6 
(FC = 2.07, P ≤ 0.05), statistically, a significant difference was 
not obtained in mRNA gene expression for these cytokines in 
patients with ENL and LL controls after treatment. The mRNA 
expression for IL-10 was significantly lower (FC  =  0.38) in 
patients with ENL than in LL patient controls (P ≤  0.0001) 
before treatment but significantly increased after treatment in 
patients with ENL (FC = 3.5) compared to LL patient controls 
and the difference was statistically significant (P ≤ 0.0001). The 
mRNA expression for TGF-β and IL-8 in patients with ENL and 
LL controls did not show statistically significant difference after 
treatment (Table 2).
Except for IL-1β and IL-10, the mRNA expression levels for 
most of these cytokines showed similar pattern both in blood 
and biopsy samples. Unlike in blood samples, the mRNA gene 
expression for IL-1β was significantly higher in the skin biopsies 
of untreated ENL patients than in LL patient controls. On the 
other hand, the gene mRNA expression for IL-10 was signifi-
cantly lower in the biopsies of untreated ENL than in LL controls 
(Table 2).
The Kinetics of cytokines gene 
expression in the Blood samples within 
enl Patient group before and after 
Treatment
The gene expression of the cytokines was also investigated in 
blood samples from patients within ENL group before and after 
treatment. The ΔΔCT of each pair was obtained by subtracting 
the ΔΔCT before treatment from ΔΔCT after treatment (ΔΔCT after  
− ΔΔCT before).
The mRNA expression for IL-8 and TGF-β did not show a 
statistically significant difference before and after treatment. On 
TaBle 4 | Cytokine mRNA expression in skin biopsy samples from patients with 
erythema nodosum leprosum before and after treatment.
cytokine ΔΔcT Fc P-value gene expression 
after treatment
TNF 2.34 0.2 <0.0001* Decreased
IFN-γ 3.03 0.12 <0.0001* Decreased
IL-1β 2.39 0.19 0.0005* Decreased
IL-6 0.31 0.81 0.6451 No change
IL-8 0.16 0.90 0.7617 No change
IL-10 −1.51 2.85 <0.0001* Increased
IL-17A 1.01 0.5 0.0204* Decreased
TGF-β 0.09 0.94 0.8337 No change
Statistical test: paired t-test, α = 0.05. ΔΔCT = delta delta CT, FC = fold change, 
* = significant at α = 0.05.
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the other hand, the gene expression levels of IFN-γ (P < 0.0001), 
IL-6 (P ≤ 0.0001), IL-1β (P ≤ 0.005), and TNF (P ≤ 0.05) were 
significantly decreased in the blood samples from patients with 
ENL after treatment while it was significantly increased for IL-10 
(P ≤ 0.0001) (Table 3).
The Kinetics of cytokines gene 
expression in the skin Biopsy samples 
within enl Patient group before and  
after Treatment
The mRNA expression in biopsy samples for TNF (P ≤ 0.0001), 
IFN-γ (P ≤ 0.0001), IL-1β (P ≤ 0.0005), and IL-17A (P ≤ 0.0204) 
were significantly decreased after prednisolone treatment. On the 
other hand, mRNA expression level for IL-10 was considerably 
increased after treatment (P ≤  0.0001). The mRNA expression 
for IL-6, IL-8, and TGF-β did not show statistically a significant 
difference before and after treatment (Table 4).
DiscUssiOn
The in vitro cytokine response of PBMCs from patients with ENL 
and LL controls to M. leprae antigen and its gene expression in 
blood and skin biopsy samples were compared before, during, 
and after treatment. Some of the key findings are discussed in the 
following paragraphs.
The analysis of ROC curve has shown that none of these 
cytokines are good enough to discriminate ENL from non-
reactional LL patient controls. This indicates that multiple cyto kines 
are involved in the pathogenesis of ENL. Among the studied 
cytokines TNF, IL-6, and IL-7A seem more powerful to discrimi-
nate ENL from LL although the discriminating power for these 
cytokines is less than 80%.
TnF
The in  vitro response of TNF to M. leprae whole-cell sonicates 
(MLWCS) in the PBMCs from patients with ENL and LL controls 
was investigated before and after treatment. The mean production 
of TNF in response to M. leprae antigen stimulation was signifi-
cantly higher (83.6.4 ± 18.8, SE pg/mL) in the culture superna-
tants of PBMCs from patients with ENL than from LL patient 
controls (19.4 pg/mL ± 10.44) before treatment. However, TNF 
production was not significantly different in these groups after 
treatment. Similar findings have been reported by several studies 
(5, 37, 38). On the other hand, the detection of TNF in plasma or 
serum samples from patients with ENL has not been consistently 
reported. Some authors did not find a significant difference in 
patients with ENL and LL controls (39, 40). Others reported that 
increased TNF production occurred during corticosteroid treat-
ment and decreased after treatment (9, 41–43). Interestingly, an 
upregulation of TNF production after thalidomide treatment of 
patients with ENL was also reported (41). These authors justified 
the increasing production of TNF during thalidomide treatment 
as an indication of immune stimulation. However, thalidomide 
and prednisolone may have different effect on the TNF. The vari-
ation of the results in various studies can be attributed to several 
factors such as experimental design, sample size, ENL definition, 
assay sensitivity, and assay methods.
In our study, the mRNA gene expression for TNF in blood 
and skin biopsies from patients with ENL was significantly 
upregulated compared to in LL controls before treatment. After 
treatment, the level of gene expression for TNF in blood and 
skin biopsy samples from patients with ENL was significantly 
decreased. Similar findings have been reported by previous 
studies (5, 21, 22, 38). On the other hand, the absence of any 
significant difference regarding the gene expression of TNF in 
the skin biopsies from patients with ENL and LL controls was 
also reported by Yamamura et al. (6).
Thus, our present kinetic study confirmed that TNF is cer-
tainly increased during ENL reactions in the same individual 
both in  vitro (following stimulation of the cells with MLWCS) 
and in vivo (increased TNF gene expression in situ). TNF is a cell 
signaling cytokine involved in systemic inflammation and it is 
one of cytokines that contribute to the acute phase reaction (27). 
However, excessive production of TNF can cause tissue injury. 
Hence, our data imply that TNF is involved in the pathogenesis of 
ENL and it may be of use for the diagnosis of ENL. Investigating 
the sources of TNF (identifying the major immune cells produc-
ing TNF) in the pathogeneses of ENL may also be important to 
explore alternative therapeutics in the future.
iFn-γ
In the present study, the mean production of IFN-γ in res-
ponse to M. leprae antigen stimulation was significantly 
higher (1361  pg/mL ±  309.6) in the culture supernatants of 
PBMCs from patients with ENL than from LL patient controls 
(280.1 pg/mL ± 269.8) before treatment (P ≤ 0.05). However, 
IFN-γ production was not significantly different in both groups 
after treatment of ENL patients. Previous independent studies 
have also reported an increasing in vitro production of IFN-γ 
in untreated patients with ENL to the response of M. leprae 
stimulation (7, 19, 44). IFN-γ mRNA gene expression in the 
blood and skin biopsies from patients with ENL was signifi-
cantly upregulated compared to in LL patient controls before 
prednisolone treatment. After treatment, the level of IFN-γ 
gene expression in the blood and skin biopsy samples from 
patients with ENL was significantly decreased. Similar findings 
have previously been reported by Iyer et  al. (7) and Moraes 
et al. (20).
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It should be noted that although fewer investigations have 
focused thus far on the role of IFN-γ, in contrast to the weight 
given to TNF, the results are more consistent and indicate an 
important role of IFN-γ in the immunopathology and occurrence 
of ENL. One earlier study has reported that administration of 
recombinant IFN-γ to patients with LL led to the development 
of ENL reactions in 60% of the patients over a 6- to 7-month 
period compared with an incidence of 15% per year with multiple 
drug therapy alone (45). Previous studies have demonstrated that 
monocyte/macrophage TNF-α production can be enhanced by 
the synergistic effect of IFN-γ (46). In addition, IFN-γ priming 
of peripheral blood monocytes from patients with leprosy has 
been demonstrated to enhance TNF-α production, both in vivo 
and in vitro (45). The mechanism by which IFN-γ induces ENL 
reactions in patients with leprosy is suggested to be through 
priming of monocytes, resulting in enhanced TNF production 
(47). IFN-γ is a major macrophage activator and a known inducer 
of macrophage TNF. It increases antigen presentation and lyso-
some activity of macrophages. However, over expression of INF-γ 
has been associated with the pathogenesis of a number of inflam-
matory and autoimmune diseases (48). The finding of increased 
INF-γ gene expression and production in untreated ENL patients 
in our study underlines the strong association between INF-γ 
and ENL reaction. Hence, IFN-γ is another candidate cytokine 
which may help to search for alternative effective drug for ENL 
treatment.
il-6
In the present study, we found that the in vitro response of IL-6 
production was substantially higher in patients with ENL than in 
LL controls before treatment. IL-6 mRNA gene expression in the 
blood and skin biopsy samples was also significantly upregulated 
in patients with ENL than in LL controls. The in vitro produc-
tion and gene expression of this cytokine was decreased after 
prednisolone treatment of patients with ENL and a significant 
difference was not observed in the two groups after treatment. 
However, its gene expression in the skin samples was not 
appreciably decreased in patients with ENL after prednisolone 
treatment. This suggests that although the systemic symptoms 
of ENL subside after treatment, there could be an ongoing 
immune response locally in the skin lesions which could take 
a longer time to establish immune homeostasis. Similar find-
ings have been reported by several authors (6, 20, 30, 49). IL-6 
is an interleukin that acts as both a pro-inflammatory and an 
anti-inflammatory cytokine which is secreted by T  cells and 
macrophages (50). It is an important cytokine-mediating fever 
and the acute phase response through its ability of crossing the 
blood–brain barrier and initiating the synthesis of prostaglandin 
E2 in the hypothalamus thereby changing the body’s temperature 
set point (51). Hence, it is sensible to assume that higher levels 
of IL-6 production could contribute to the development of ENL 
reactions in non-reactional LL patients mainly owing to the 
potent pro-inflammatory role of IL-6 and its capacity to stimu-
late antibody production. The increased production of IL-6 in 
ENL reactions due to polymorphisms in the genes encoding the 
cytokine has been suggested (52). Based on the multiple effects 
of IL-6 on the control of innate and adaptive immune responses, 
its potential contribution to the immunopathogenesis of ENL 
reaction needs to be explored further.
il-8
In this study, higher in vitro production of IL-8 to the response 
of PBMCs stimulation to M. leprae was obtained in patients with 
ENL than in LL controls before, during, and after prednisolone 
treatment. Unlike the other cytokines studied, IL-8 production 
did not decrease during and after prednisolone treatment of 
patients with ENL. The mRNA gene expression of IL-8 both in the 
blood and skin biopsy samples was also significantly upregulated 
in patients with ENL before, during, and after prednisolone treat-
ment. Few studies have investigated the role IL-8 from serum in 
the immunopathogenesis of ENL by comparing its production 
and gene expression. IL-8 mRNA upregulation in untreated 
patients with ENL has been previously reported by some authors 
(6) and its in vitro production (31) and both studies are in agree-
ment with our finding.
IL-8 (CXCL8) is a chemokine produced mainly by macrophages 
and plays a key role in inflammation in neutrophil recruitment 
and inducer of phagocytosis. Studies have shown that anti-IL-8 
treatment prevent neutrophil-dependent tissue damage as well 
as neutrophil infiltration in several types of acute inflammatory 
reactions, including lipopolysaccharide (LPS)-induced dermati-
tis, LPS/IL-1-induced arthritis and acute immune complex-type 
glomerulonephritis (53).
Thus, the finding of increased IL-8 production as well as 
IL-8 mRNA gene expression in the blood and skin lesions from 
patients with ENL suggests a potential role for this chemokine in 
the pathogenesis of ENL. Hence, exploring the potential role of 
IL-8 in the immunopathogenesis of ENL may provide valuable 
information in the diagnosis and treatment of ENL.
il-17
The in vitro production of IL-17A in PBMC samples and IL-17 
mRNA gene expression in the blood and skin biopsy samples 
from patients with ENL was significantly increased before 
treatment and decreased after prednisolone treatment. IL-17A 
is the least studied cytokine in ENL reaction. Recently a cross-
sectional study has reported that increased IL-17A production to 
M. leprae stimulation in ENL patients compared to non-reactional 
LL patients (26). One study has reported the upregulation of 
IL-17A before and after thalidomide treatment of ENL patients 
(24). However, the effect of thalidomide on IL-17A expression 
may be different from that of prednisolone. IL-17A is an immu-
noregulatory cytokine capable of promoting the generation of 
pro-inflammatory cytokines and chemokines, which leads to the 
attraction of neutrophils and macrophages to the inflammation 
site (54). The finding of increased IL-17A production and its 
mRNA gene expression in patients with ENL in the present study 
shows the involvement of IL-17A in the pathogenesis of ENL 
reaction. Hence, understanding the exact role of this cytokine 
in ENL reaction will benefit the development of novel immune 
modulators that reduce inflammation and thereby protect tissue 
damage in patients with ENL.
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il-10
The in vitro production of IL-10 in response to M. leprae stimula-
tion in the PBMCs of patients with ENL was significantly lower 
than that in LL controls before treatment. After prednisolone 
treatment of ENL patients, IL-10 production was significantly 
increased and it was higher than the value obtained in LL 
controls. The present result is in agreement with Sampaio et al. 
(38). Although IL-10 mRNA gene expression in the blood 
samples before and after treatment in patients with ENL and LL 
controls did not reveal a statistically significantly different result, 
the longitudinal comparison in patients with ENL has shown 
significantly increased IL-10 mRNA gene expression after pred-
nisolone treatment similar to the in vitro IL-10 production. On 
the other hand, unlike the blood samples, the gene expression in 
skin biopsy samples was significantly decreased before treatment 
in patients with ENL compared to LL controls and considerably 
increased after prednisolone treatment. Therefore, it seems that 
IL-10 regulates excess immune response locally in the skin than 
systemically in the blood. Variable and inconstant reports have 
been published on serum or plasma IL-10 production in patients 
with ENL. Increased IL-10 production in patients with ENL has 
been reported by some authors (9, 40). Other studies failed to 
detect any differences in serum IL-10 between patients with ENL 
and LL controls (7, 25, 43) or in IL-10 mRNA in biopsy skin 
specimens (22).
IL-10 is a well-known cytokine involved in downregulating 
macrophage functions. IL-10 has been shown to inhibit cytokine 
synthesis by monocytes, namely TNF-α, IL-1, IL-6, IL-8, and 
IL-12 (38). Thus, the finding of decreased IL-10 production as 
well as IL-10 gene expression in untreated patients with ENL 
reaction implies the loss of control over these pro-inflammatory 
cytokines which exacerbates ENL reactions.
In conclusion, the in vitro production and gene expression of 
the cytokines: TNF, IFN-γ, IL-6, IL-8, and IL-17A were signifi-
cantly increased in untreated patients with ENL at recruitment. 
However, IL-10 production and gene expression was significantly 
lower in untreated ENL patients and significantly increased after 
prednisolone treatment. This is the first study examining the 
effect of prednisolone on the kinetics of inflammatory cytokines 
in patients with ENL reactions before and after treatment. 
Our findings suggest that prednisolone modulates the pro- 
inflammatory cytokines studied here either directly or through 
suppressing the immune cells producing these inflammatory 
cytokines. This needs further confirmation through identification 
of the immune cells producing these cytokines. Prednisolone 
is extensively used for treatment of ENL reactions, but clinical 
improvement varies, and a better understanding of the immunol-
ogy of ENL is required to improve treatment for these patients. 
Although the immune response to M. leprae is cytokine mediated, 
the involvement of cytokines in ENL reactions is less understood. 
Our data clearly suggest that cytokines are involved in ENL 
reaction, yet the sources of these cytokines are unknown. If 
prednisolone effectively switch off these inflammatory cytokines, 
why some ENL patients do not show clinical improvement to 
prednisolone treatment? Therefore, cytokines may not be the 
only key players in the pathogenesis of ENL. There could be other 
factors or modulators other than cytokines which take part in the 
immunopathogenesis of ENL. These assumptions need to be fur-
ther investigated and we need to understand how prednisolone 
works with cytokines which could lead us to better drugs that 
effectively resolve inflammation more rapidly.
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